Adam  Elsesser net worth and biography

Adam Elsesser Biography and Net Worth

President, Chairman and CEO of Penumbra
Adam co-founded Penumbra and has served as Chief Executive Officer and a member of our board of directors since our inception in 2004, as Chairman of our board of directors since January 2015. He resumed the role of President in May 2020, previously serving as President from January 2015 until August 2019. Prior to Penumbra, Adam led SMART Therapeutics, Inc., a medical device company focused on devices for neuro-intervention, as its Chief Executive Officer from 2000 to 2002 and, after its acquisition by Boston Scientific Corporation, President of SMART Therapeutics within Boston Scientific Corporation from 2002 to 2005. Before his work in the medical device industry, Adam was a partner in the law firm of Shartsis Friese LLP. He received a BA from Stanford University and a JD from Hastings College of the Law.

What is Adam Elsesser's net worth?

The estimated net worth of Adam Elsesser is at least $208.76 million as of November 20th, 2024. Mr. Elsesser owns 852,582 shares of Penumbra stock worth more than $208,763,229 as of December 3rd. This net worth estimate does not reflect any other investments that Mr. Elsesser may own. Additionally, Mr. Elsesser receives an annual salary of $601,620.00 as President, Chairman and CEO at Penumbra. Learn More about Adam Elsesser's net worth.

How old is Adam Elsesser?

Mr. Elsesser is currently 62 years old. There are 3 older executives and no younger executives at Penumbra. Learn More on Adam Elsesser's age.

What is Adam Elsesser's salary?

As the President, Chairman and CEO of Penumbra, Inc., Mr. Elsesser earns $601,620.00 per year. There are 2 executives that earn more than Mr. Elsesser. The highest earning executive at Penumbra is Ms. Maggie S. Yuen, Chief Financial Officer, who commands a salary of $666,040.00 per year. Learn More on Adam Elsesser's salary.

How do I contact Adam Elsesser?

The corporate mailing address for Mr. Elsesser and other Penumbra executives is One Penumbra Place, Alameda CA, 94502. Penumbra can also be reached via phone at (510) 748-3200 and via email at [email protected]. Learn More on Adam Elsesser's contact information.

Has Adam Elsesser been buying or selling shares of Penumbra?

During the past quarter, Adam Elsesser has sold $6,627,600.00 in shares of Penumbra stock. Most recently, Adam Elsesser sold 15,000 shares of the business's stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $237.28, for a transaction totalling $3,559,200.00. Following the completion of the sale, the chief executive officer now directly owns 852,582 shares of the company's stock, valued at $202,300,656.96. Learn More on Adam Elsesser's trading history.

Who are Penumbra's active insiders?

Penumbra's insider roster includes Arani Bose (Insider), Adam Elsesser (President, Chairman and CEO), Harpreet Grewal (Director), Don Kassing (Director), Bridget O'Rourke (Director), James Pray (Insider), Johanna Roberts (EVP), Surbhi Sarna (Director), and Thomas Wilder (Director). Learn More on Penumbra's active insiders.

Are insiders buying or selling shares of Penumbra?

In the last twelve months, insiders at the sold shares 22 times. They sold a total of 91,671 shares worth more than $19,415,521.66. The most recent insider tranaction occured on November, 20th when CEO Adam Elsesser sold 15,000 shares worth more than $3,559,200.00. Insiders at Penumbra own 5.0% of the company. Learn More about insider trades at Penumbra.

Information on this page was last updated on 11/20/2024.

Adam Elsesser Insider Trading History at Penumbra

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/20/2024Sell15,000$237.28$3,559,200.00852,582View SEC Filing Icon  
10/21/2024Sell15,000$204.56$3,068,400.00867,582View SEC Filing Icon  
9/20/2024Sell15,000$197.71$2,965,650.00882,582View SEC Filing Icon  
8/22/2024Sell1,620$200.00$324,000.00925,962View SEC Filing Icon  
7/17/2024Sell15,000$202.52$3,037,800.00927,582View SEC Filing Icon  
5/20/2024Sell15,000$200.98$3,014,700.00942,582View SEC Filing Icon  
10/11/2023Sell9,670$215.76$2,086,399.20View SEC Filing Icon  
9/11/2023Sell9,666$298.76$2,887,814.16View SEC Filing Icon  
8/11/2023Sell9,666$247.21$2,389,531.86View SEC Filing Icon  
7/11/2023Sell9,666$322.98$3,121,924.68View SEC Filing Icon  
6/12/2023Sell9,666$324.49$3,136,520.34View SEC Filing Icon  
5/11/2023Sell9,666$318.52$3,078,814.32View SEC Filing Icon  
1/11/2022Sell14,500$253.34$3,673,430.00View SEC Filing Icon  
12/13/2021Sell14,500$248.95$3,609,775.00View SEC Filing Icon  
11/11/2021Sell14,500$264.18$3,830,610.00View SEC Filing Icon  
10/11/2021Sell14,500$254.60$3,691,700.00View SEC Filing Icon  
9/13/2021Sell14,500$280.42$4,066,090.00View SEC Filing Icon  
8/11/2021Sell14,500$251.24$3,642,980.0014,500View SEC Filing Icon  
12/11/2020Sell8,000$190.70$1,525,600.00View SEC Filing Icon  
11/11/2020Sell8,000$265.16$2,121,280.00View SEC Filing Icon  
10/12/2020Sell8,000$212.64$1,701,120.00View SEC Filing Icon  
9/11/2020Sell8,000$200.73$1,605,840.00View SEC Filing Icon  
8/11/2020Sell8,000$232.15$1,857,200.00View SEC Filing Icon  
7/13/2020Sell8,000$191.90$1,535,200.00View SEC Filing Icon  
6/11/2020Sell8,000$166.88$1,335,040.00View SEC Filing Icon  
5/11/2020Sell8,000$187.67$1,501,360.00View SEC Filing Icon  
4/13/2020Sell8,000$157.81$1,262,480.00View SEC Filing Icon  
3/9/2020Sell8,000$172.01$1,376,080.00View SEC Filing Icon  
12/11/2019Sell8,000$156.64$1,253,120.00View SEC Filing Icon  
11/11/2019Sell8,000$168.70$1,349,600.00View SEC Filing Icon  
10/11/2019Sell8,000$146.06$1,168,480.00View SEC Filing Icon  
9/11/2019Sell8,000$144.67$1,157,360.00View SEC Filing Icon  
8/12/2019Sell8,000$149.24$1,193,920.00View SEC Filing Icon  
7/11/2019Sell8,000$171.84$1,374,720.00View SEC Filing Icon  
6/11/2019Sell8,000$165.08$1,320,640.00View SEC Filing Icon  
5/13/2019Sell8,000$125.30$1,002,400.00View SEC Filing Icon  
4/11/2019Sell8,000$141.58$1,132,640.00View SEC Filing Icon  
3/11/2019Sell8,000$139.86$1,118,880.001,115,838View SEC Filing Icon  
11/28/2017Sell10,000$103.95$1,039,500.001,121,356View SEC Filing Icon  
11/24/2017Sell10,135$105.10$1,065,188.501,133,672View SEC Filing Icon  
11/22/2017Sell5,051$105.98$535,304.981,133,672View SEC Filing Icon  
11/20/2017Sell62,862$105.15$6,609,939.301,191,887View SEC Filing Icon  
11/17/2017Sell11,186$103.56$1,158,422.161,191,887View SEC Filing Icon  
11/15/2017Sell24,444$105.83$2,586,908.521,231,338View SEC Filing Icon  
2/13/2017Sell7,700$72.21$556,017.001,241,938View SEC Filing Icon  
2/1/2017Sell21,400$70.98$1,518,972.001,244,038View SEC Filing Icon  
1/31/2017Sell9,000$71.26$641,340.001,244,038View SEC Filing Icon  
1/30/2017Sell8,200$70.72$579,904.001,244,038View SEC Filing Icon  
9/9/2016Sell57,200$71.07$4,065,204.001,249,838View SEC Filing Icon  
8/31/2016Sell26,000$71.15$1,849,900.001,244,838View SEC Filing Icon  
8/26/2016Sell26,800$71.06$1,904,408.001,244,638View SEC Filing Icon  
8/24/2016Sell29,000$72.95$2,115,550.001,245,938View SEC Filing Icon  
See Full Table

Adam Elsesser Buying and Selling Activity at Penumbra

This chart shows Adam Elsesser's buying and selling at Penumbra by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Penumbra Company Overview

Penumbra logo
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Read More

Today's Range

Now: $245.94
Low: $242.70
High: $246.70

50 Day Range

MA: $217.76
Low: $186.89
High: $248.96

2 Week Range

Now: $245.94
Low: $148.00
High: $277.34

Volume

49,694 shs

Average Volume

377,345 shs

Market Capitalization

$9.44 billion

P/E Ratio

285.98

Dividend Yield

N/A

Beta

0.51